AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11581545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and behavioral weight management (WM)
Number of subjects: 112
Study 11581545 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only group (EX)
Number of subjects: 112
Study 11581545 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (CON)
Number of subjects: 112
Study 9734739 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals containing beta-carotene sources (mainly red sweet potatoes) and added fat, with deworming using levamisole.
Number of subjects: 0
Study 9734739 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals containing beta-carotene sources and added fat without deworming.
Number of subjects: 0
Study 9734739 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals with added beta-carotene sources and added fat when A. lumbricoides infection was low.
Number of subjects: 0
Study 9734739 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who remained infected with A. lumbricoides and did not receive deworming).
Number of subjects: 0
Study 7825525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoprotein
Number of subjects: 0
Study 7825525 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2596424 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Only (DO)
Number of subjects: 24
Study 2596424 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with Exercise (DE)
Number of subjects: 24
Study 2596424 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - Balanced, moderately low-calorie diet (approximately 1400 kcal/d)
Number of subjects: 24
Study 653482 — intervention group
Group type: EXPERIMENTAL
Intervention: Exteriorization and closure of the penetrating colon wound
Number of subjects: 34
Study 653482 — intervention group
Group type: COMPARATOR
Intervention: Colostomy
Number of subjects: 34
Study 31965646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-dense formula (NDF)
Number of subjects: 48
Study 31965646 — intervention group
Group type: COMPARATOR
Intervention: Post-discharge formula (PDF)
Number of subjects: 48
Study 30781543 — intervention group
Group type: EXPERIMENTAL
Intervention: TEI Program (peer tutoring intervention)
Number of subjects: 2057
Study 30781543 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 schools, 1070 students)
Number of subjects: 2057
Study 28900096 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth-I (B-I) anastomosis
Number of subjects: 140
Study 28900096 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y (R-Y) anastomosis
Number of subjects: 140
Study 25824637 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (1,140 mg of EPA + 600 mg of DHA)
Number of subjects: 35
Study 25824637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil + safflower oil)
Number of subjects: 35
Study 25286455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia (defined by low muscle mass, low muscle strength, and low physical performance)
Number of subjects: 1149
Study 25286455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynapenia (defined by low handgrip strength)
Number of subjects: 1149
Study 25286455 — intervention group
Group type: COMPARATOR
Intervention: No sarcopenia
Number of subjects: 1149
Study 25286455 — intervention group
Group type: COMPARATOR
Intervention: No dynapenia
Number of subjects: 1149
Study 21854132 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g twice a day/week)
Number of subjects: 310
Study 21854132 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (300 mg twice a day/week)
Number of subjects: 310
Study 19619424 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive system (Scotchbond Multipurpose)
Number of subjects: 48
Study 19619424 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide liner (Dycal)
Number of subjects: 48
Study 17593672 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 75
Study 17593672 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone nasal spray
Number of subjects: 75
Study 17593672 — intervention group
Group type: COMPARATOR
Intervention: Steam inhalation (Control)
Number of subjects: 75
Study 15139896 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 35
Study 15139896 — intervention group
Group type: COMPARATOR
Intervention: High glycaemic index diet
Number of subjects: 35
Study 12034622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-phase helical CT
Number of subjects: 60
Study 12034622 — intervention group
Group type: COMPARATOR
Intervention: Single-phase helical CT
Number of subjects: 60
Study 11372148 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 60
Study 11372148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pako Ijebu (Massularia acuminata)
Number of subjects: 60
Study 11372148 — intervention group
Group type: EXPERIMENTAL
Intervention: Orin Ayan (Distemonanthus benthamianus)
Number of subjects: 60
Study 8085464 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300‐450 mg/day)
Number of subjects: 209
Study 8085464 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20‐40 mg/day)
Number of subjects: 209
Study 2751139 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mg.kg‐1 caudal morphine
Number of subjects: 32
Study 2751139 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.067 mg.kg‐1 caudal morphine
Number of subjects: 32
Study 2751139 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.033 mg.kg‐1 caudal morphine
Number of subjects: 32
Study 2751139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric drainage
Number of subjects: 32
Study 1098499 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 47
Study 1098499 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 47
Study 1098499 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (2.0 g course)
Number of subjects: 47
Study 31786695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetero- or homozygosity for the allelic variant TLR6 (P249S) in patients with large abscesses
Number of subjects: 253
Study 31786695 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygosity for the allelic variant TLR1 (R80T) in patients with large abscesses
Number of subjects: 253
Study 31786695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetero- or homozygosity for the allelic variant TLR1 (S248N) in patients with DFIs
Number of subjects: 253
Study 31786695 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in TLR1 and TLR6
Number of subjects: 253
Study 31786695 — intervention group
Group type: COMPARATOR
Intervention: PEDIS infection score
Number of subjects: 253
Study 31576433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg
Number of subjects: 31
Study 31576433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 960 mg
Number of subjects: 31
Study 28295989 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/ml liquid formulation of 6-mercaptopurine (6-MP)
Number of subjects: 22
Study 28295989 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/ml liquid formulation of 6-mercaptopurine (6-MP)
Number of subjects: 22
Study 28295989 — intervention group
Group type: COMPARATOR
Intervention: Marketed 50 mg 6-MP tablet
Number of subjects: 22
Study 25181451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) starting titration at 200 μg
Number of subjects: 442
Study 25181451 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl buccal tablet (FBT) starting titration at 100 μg
Number of subjects: 442
Study 25181451 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective doses of FBT
Number of subjects: 442
Study 25181451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) at doses up to 800 μg
Number of subjects: 442
Study 24490266 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily for 18 months)
Number of subjects: 286
Study 24490266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 24490266 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 286
Study 21474277 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected relaxation (ER)
Number of subjects: 79
Study 21474277 — intervention group
Group type: COMPARATOR
Intervention: Expected arousal (EA)
Number of subjects: 79
Study 21474277 — intervention group
Group type: COMPARATOR
Intervention: Low-AS with expected relaxation (ER)
Number of subjects: 79
Study 21474277 — intervention group
Group type: COMPARATOR
Intervention: Low-AS with expected arousal (EA)
Number of subjects: 79
Study 19087583 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon3 self-ligating brackets
Number of subjects: 26
Study 19087583 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 26
Study 16581477 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up exercise (WEx) before cold exposure
Number of subjects: 15
Study 16581477 — intervention group
Group type: COMPARATOR
Intervention: Weight-bearing exercise before cold exposure
Number of subjects: 15
Study 15252267 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 600-mg split dose (400 mg at 7 AM; 200 mg at noon)
Number of subjects: 24
Study 15252267 — intervention group
Group type: COMPARATOR
Intervention: Modafinil 400-mg once daily (7 AM) plus placebo (noon)
Number of subjects: 24
Study 15252267 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (both dosing strategies)
Number of subjects: 24
Study 11511287 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1% ophthalmic solution
Number of subjects: 15
Study 11511287 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 9266878 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cytologic assessment during CT-guided FNAC (Group A, 110 patients)
Number of subjects: 220
Study 9266878 — intervention group
Group type: COMPARATOR
Intervention: No immediate cytologic examination, only gross assessment by the surgeon (Group B, 110 patients)
Number of subjects: 220
Study 9266878 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for both groups
Number of subjects: 220
Study 8016009 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil (50 mg, oral administration)
Number of subjects: 10
Study 8016009 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil (5 mg, intravenous infusion)
Number of subjects: 10
Study 2648152 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml or 50 ml of fish oil (3 or 15 g of n‐3 fatty acids)
Number of subjects: 32
Study 2648152 — intervention group
Group type: COMPARATOR
Intervention: 50 ml of safflower oil (39 g of n‐6 fatty acids)
Number of subjects: 32
Study 2648152 — intervention group
Group type: COMPARATOR
Intervention: 50 ml of a mixture of oils that approximated the types of fat present in the American diet
Number of subjects: 32
Study 30972436 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-thalassaemia major patients
Number of subjects: 38
Study 30972436 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-thalassaemia major patients with significant myocardial iron overload
Number of subjects: 38
Study 30972436 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study 28985425 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 96
Study 25377629 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time, focused educational interventions by physician peers in addition to usual training
Number of subjects: 44
Study 25377629 — intervention group
Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 44
Study 21546277 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited bowel preparation (BP) method: liberal use of liquid diet, sodium phosphate laxative, and self-administered enema the day before surgery.
Number of subjects: 112
Study 21546277 — intervention group
Group type: COMPARATOR
Intervention: 3-day conventional bowel preparation (BP) method: diet restriction, oral antibiotics, oral laxatives, and saline enemas over a 3-day period.
Number of subjects: 112
Study 22111945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVTA)
Number of subjects: 40
Study 19922311 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP combined with 125I seed implantation
Number of subjects: 80
Study 19922311 — intervention group
Group type: COMPARATOR
Intervention: PVP alone
Number of subjects: 80
Study 16859579 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (IL-2) at dose level 1: 4 MIU/m2 per day, every other week for 24 weeks (n = 10)
Number of subjects: 41
Study 16859579 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (IL-2) at dose level 2: 8 MIU/m2 per day, every other week for 24 weeks (n = 9)
Number of subjects: 41
Study 16859579 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (IL-2) at dose level 3: 4 MIU/m2 per day, weeks 1-4, 9-12, and 17-20 (n = 11)
Number of subjects: 41
Study 16859579 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interleukin-2 (IL-2) at dose level 4: 8 MIU/m2 per day, weeks 1-4, 9-12, and 17-20 (n = 10)
Number of subjects: 41
Study 16859579 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy of IL-2 treatment
Number of subjects: 41
Study 12560953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem bicycle
Number of subjects: 7
Study 12560953 — intervention group
Group type: COMPARATOR
Intervention: Chair apparatus
Number of subjects: 7
Study 10986302 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 159
Study 10986302 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Gold (GST)
Number of subjects: 159
Study 10986302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SSZ)
Number of subjects: 159
Study 10986302 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 159
Study 10986302 — intervention group
Group type: COMPARATOR
Intervention: Cox proportional hazards test for all withdrawals
Number of subjects: 159
Study 10986302 — intervention group
Group type: COMPARATOR
Intervention: Observational studies vs RCTs
Number of subjects: 159
Study 9312310 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg) after food
Number of subjects: 15
Study 9312310 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide (50 mg) after fasting
Number of subjects: 15
Study 8379864 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal nerve blockade with 0.5% bupivacaine with adrenaline and xylocaine 1%
Number of subjects: 30
Study 8379864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abdominal nerve blockade)
Number of subjects: 30
Study 3665121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 16
Study 3665121 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 16
Study 30930587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Traction (CT)
Number of subjects: 75
Study 30930587 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse Oscillatory Pressure (TOP)
Number of subjects: 75
Study 30930587 — intervention group
Group type: COMPARATOR
Intervention: Control (Cnt)
Number of subjects: 75
Study 29098249 — intervention group
Group type: EXPERIMENTAL
Intervention: Free dental filling intervention (oral health examination and free filling of shallow and moderate caries once a year for 3 years)
Number of subjects: 918
Study 29098249 — intervention group
Group type: COMPARATOR
Intervention: Oral health examination only (once a year)
Number of subjects: 918
Study 26251005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi program
Number of subjects: 266
Study 23437905 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education and training (lecture and hands-on training)
Number of subjects: 30
Study 23437905 — intervention group
Group type: COMPARATOR
Intervention: Facilitated group discussion (control)
Number of subjects: 30
Study 20331370 — intervention group
Group type: EXPERIMENTAL
Intervention: Acapella
Number of subjects: 23
Study 20331370 — intervention group
Group type: COMPARATOR
Intervention: PEP mask
Number of subjects: 23
Study 20331370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 23
Study 18779677 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 310
Study 18779677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 16644897 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal postal intervention (general information letter and questionnaire)
Number of subjects: 990
Study 16644897 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal postal intervention
Number of subjects: 990
Study 12525442 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 5 mg mifepristone per day for 120 days
Number of subjects: 90
Study 10805319 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 60536
Number of subjects: 0
Study 8877932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg tid
Number of subjects: 135
Study 8877932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg bid
Number of subjects: 135
Study 8877932 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg tid
Number of subjects: 135
Study 8877932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg tid (follow-up)
Number of subjects: 135
Study 8877932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg bid (follow-up)
Number of subjects: 135
Study 1642079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-acting insulin twice daily (2-dose)
Number of subjects: 10
Study 1642079 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial regular insulin and intermediate-acting insulin at bedtime (4-dose)
Number of subjects: 10
Study 1642079 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (before insulin treatment)
Number of subjects: 10
Study 6673724 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol powder (400 micrograms)
Number of subjects: 10
Study 6673724 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline aerosol (500 micrograms)
Number of subjects: 10
Study 6673724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 10
Study 30883357 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Argentine Tango intervention (12 weeks, 20 lessons)
Number of subjects: 30
Study 30883357 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group (N=10)
Number of subjects: 30
Study 30532278 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric breast pump
Number of subjects: 30
Study 26830414 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAY Project plus Community Standard (CS) Treatment
Number of subjects: 112
Study 26830414 — intervention group
Group type: COMPARATOR
Intervention: Community Standard (CS) Treatment
Number of subjects: 112
Study 24249320 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HCT) with myeloablative conditioning in 36 patients
Number of subjects: 60
Study 24249320 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HCT) with reduced-intensity conditioning (RIC) in 24 patients
Number of subjects: 60
Study 24249320 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GvHD) prophylaxis with methotrexate and cyclosporine A in 36 patients
Number of subjects: 60
Study 24249320 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GvHD) prophylaxis with cyclosporine A plus mycophenolate mofetil in 24 patients
Number of subjects: 60
Study 22313548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 100
Study 22313548 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor (H-GPI)
Number of subjects: 100
Study 19804591 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin protection regimen (skin care + skin protection)
Number of subjects: 800
Study 19804591 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin protection alone
Number of subjects: 800
Study 19804591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no recommendation)
Number of subjects: 800
Study 16936707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin aspart (ASP‐I) 40 IU acute and 4 x 40 IU/day over 8 weeks
Number of subjects: 36
Study 16936707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal regular human insulin (RH‐I) 40 IU acute and 4 x 40 IU/day over 8 weeks
Number of subjects: 36
Study 16936707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16281077 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-80
Number of subjects: 251
Study 16281077 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-83
Number of subjects: 251
Study 16281077 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-87
Number of subjects: 251
Study 16281077 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-91
Number of subjects: 251
Study 16281077 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-97
Number of subjects: 251
Study 12131215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 34
Study 12131215 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitors (PI)
Number of subjects: 34
Study 10213008 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (Campto)
Number of subjects: 0
Study 10213008 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 10213008 — intervention group
Group type: COMPARATOR
Intervention: High-dose 5-fluorouracil (5-FU) infusion
Number of subjects: 0
Study 7631635 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seroprevalence among women
Number of subjects: 0
Study 7631635 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seroprevalence among men
Number of subjects: 0
Study 7631635 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of male patients reporting vaginal intercourse
Number of subjects: 0
Study 7631635 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of male patients reporting receptive oral sex
Number of subjects: 0